Assessment uncovers tp53 alterations and effects of chemotherapy in waldenström macroglobulinemia patients, indicating heightened risk of poor outcomes.
Key Points
Ultrahigh-risk waldenström macroglobulinemia patients exhibit double-hit tp53 alterations, suggesting an association with worse outcomes.
Patients with tp53 mutations showed a significantly lower overall survival rate compared to tp53 wild-type patients at 9 years.
Logistic regression analysis demonstrated a link between prior chemotherapy and acquisition of tp53 alterations and mutations.
Multivariate analysis confirmed double-hit tp53 alterations as a key predictor for overall survival in this patient group.